Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor.

Literature DB >> 1337334

Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor.

P F Piguet¹, G E Grau, C Vesin, H Loetscher, R Gentz, W Lesslauer.

Abstract

Immunization of DBA/1 mice with type II collagen within complete Freund's adjuvant leads to arthritis, lasting more than 3 months. Injection of anti-tumour necrosis factor (TNF) IgG, 2 and 3 weeks after immunization prevented the development of arthritis in the following months. This treatment had no effect when started 2 months after induction of the disease. A soluble form of the human recombinant TNF receptor type-beta (rsTNFR-beta), continuously infused at a rate of 20 micrograms/day during the second and third week after immunization, also had a long-term protective effect. Anti-TNF antibody had no effect upon the production of anti-type II collagen antibodies. These results indicate that TNF is critically involved in an early phase of this arthritis.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1992 PMID： 1337334 PMCID： PMC1421669

Source DB: PubMed Journal: Immunology ISSN： 0019-2805 Impact factor: 7.397

24 in total

1. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.

Authors: D R Bertolini; G E Nedwin; T S Bringman; D D Smith; G R Mundy
Journal: Nature Date: 1986 Feb 6-12 Impact factor: 49.962

Review 2. Collagen autoimmunity and arthritis.

Authors: J M Stuart; W C Watson; A H Kang
Journal: FASEB J Date: 1988-11 Impact factor: 5.191

3. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.

Authors: F M Brennan; D Chantry; A Jackson; R Maini; M Feldmann
Journal: Lancet Date: 1989-07-29 Impact factor: 79.321

Review 4. The biology of cachectin/TNF--a primary mediator of the host response.

Authors: B Beutler; A Cerami
Journal: Annu Rev Immunol Date: 1989 Impact factor: 28.527

5. Phagocytosis and inflammatory stimuli induce GM-CSF mRNA in macrophages through posttranscriptional regulation.

Authors: B Thorens; J J Mermod; P Vassalli
Journal: Cell Date: 1987-02-27 Impact factor: 41.582

6. Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity.

Authors: H Loetscher; R Gentz; M Zulauf; A Lustig; H Tabuchi; E J Schlaeger; M Brockhaus; H Gallati; M Manneberg; W Lesslauer
Journal: J Biol Chem Date: 1991-09-25 Impact factor: 5.157

7. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.

Authors: P F Piguet; M A Collart; G E Grau; Y Kapanci; P Vassalli
Journal: J Exp Med Date: 1989-09-01 Impact factor: 14.307

8. Interleukin 6 production in experimental cerebral malaria: modulation by anticytokine antibodies and possible role in hypergammaglobulinemia.

Authors: G E Grau; K Frei; P F Piguet; A Fontana; H Heremans; A Billiau; P Vassalli; P H Lambert
Journal: J Exp Med Date: 1990-11-01 Impact factor: 14.307

9. Genetic susceptibility to murine collagen II autoimmune arthritis. Proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatibility complex (MHC) and non-MHC loci.

Authors: W C Watson; A S Townes
Journal: J Exp Med Date: 1985-12-01 Impact factor: 14.307

10. Tumor necrosis factor is a critical mediator in hapten induced irritant and contact hypersensitivity reactions.

Authors: P F Piguet; G E Grau; C Hauser; P Vassalli
Journal: J Exp Med Date: 1991-03-01 Impact factor: 14.307

55 in total

Review 1. Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha.

Authors: R O Williams; M Feldmann; R N Maini
Journal: Ann Rheum Dis Date: 2000-11 Impact factor: 19.103

2. The tyrosine kinase inhibitor tyrphostin AG126 reduces the development of acute and chronic inflammation.

Authors: S Cuzzocrea; M C McDonald; E Mazzon; D Siriwardena; G Calabrò; D Britti; G Mazzullo; A De Sarro; A P Caputi; C Thiemermann
Journal: Am J Pathol Date: 2000-07 Impact factor: 4.307

3. Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats.

Authors: S Cuzzocrea; E Mazzon; C Bevilaqua; G Costantino; D Britti; G Mazzullo; A De Sarro; A P Caputi
Journal: Br J Pharmacol Date: 2000-12 Impact factor: 8.739

Review 4. Analysing the effect of novel therapies on cytokine expression in experimental arthritis.

Authors: Richard O Williams; Julia J Inglis; Egle Simelyte; Gabriel Criado; Percy F Sumariwalla
Journal: Int J Exp Pathol Date: 2005-10 Impact factor: 1.925

5. The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor α and counter-regulated by the synovial fluid microenvironment.

Authors: Rachael A Gordon; Galina Grigoriev; Angela Lee; George D Kalliolias; Lionel B Ivashkiv
Journal: Arthritis Rheum Date: 2012-10

6. The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis.

Authors: A C Issekutz; A Meager; I Otterness; T B Issekutz
Journal: Clin Exp Immunol Date: 1994-07 Impact factor: 4.330